BACKGROUND:Oral rhesus/rhesus-human reassortant rotavirus tetravalent vaccine (RRV-TV) was licensed in 1998 but withdrawn in 1999 due to a rare association with intussusception, which occurred disproportionately in infants receiving their first dose at ≥90 days of age. This study examined RRV-TV for the prevention of rotavirus gastroenteritis (RV-GE) in Ghana, West Africa, with infants receiving the first dose during the neonatal period and the second before 60 days of age. METHODS: In a double-blinded, randomized, placebo-controlled trial in Navrongo, Ghana, we recruited neonates to receive 2 doses of RRV-TV or placebo and followed them to age 12 months. RESULTS: In the intention-to-treat population of 998 infants, we measured a vaccine efficacy of 63.1% against RV-GE of any severity associated with any of the 4 serotypes represented in the vaccine and 60.7% against RV-GE associated with any rotavirus serotype. CONCLUSIONS: RRV-TV in a 2-dose schedule with the first dose during the neonatal period is efficacious in preventing RV-GE in rural Ghana. Neonatal dosing results in early protection and may be the optimum schedule to avoid or significantly reduce intussusception, now reported to be associated in international settings with the 2 most widely marketed, licensed, live virus, oral rotavirus vaccines.
RCT Entities:
BACKGROUND: Oral rhesus/rhesus-human reassortant rotavirus tetravalent vaccine (RRV-TV) was licensed in 1998 but withdrawn in 1999 due to a rare association with intussusception, which occurred disproportionately in infants receiving their first dose at ≥90 days of age. This study examined RRV-TV for the prevention of rotavirus gastroenteritis (RV-GE) in Ghana, West Africa, with infants receiving the first dose during the neonatal period and the second before 60 days of age. METHODS: In a double-blinded, randomized, placebo-controlled trial in Navrongo, Ghana, we recruited neonates to receive 2 doses of RRV-TV or placebo and followed them to age 12 months. RESULTS: In the intention-to-treat population of 998 infants, we measured a vaccine efficacy of 63.1% against RV-GE of any severity associated with any of the 4 serotypes represented in the vaccine and 60.7% against RV-GE associated with any rotavirus serotype. CONCLUSIONS:RRV-TV in a 2-dose schedule with the first dose during the neonatal period is efficacious in preventing RV-GE in rural Ghana. Neonatal dosing results in early protection and may be the optimum schedule to avoid or significantly reduce intussusception, now reported to be associated in international settings with the 2 most widely marketed, licensed, live virus, oral rotavirus vaccines.
Authors: Brian R Murphy; David M Morens; Lone Simonsen; Robert M Chanock; John R La Montagne; Albert Z Kapikian Journal: J Infect Dis Date: 2003-04-02 Impact factor: 5.226
Authors: R L Ward; D I Bernstein; R Shukla; E C Young; J R Sherwood; M M McNeal; M C Walker; G M Schiff Journal: J Infect Dis Date: 1989-01 Impact factor: 5.226
Authors: Ezzeldin Saleh; Brian Eichner; Douglas W Clark; Martha E Gagliano; James M Troutman; Lynn Harrington; Monica McNeal; Dennis Clements Journal: J Pediatric Infect Dis Soc Date: 2018-02-19 Impact factor: 3.164
Authors: Marion S Tissera; Daniel Cowley; Nada Bogdanovic-Sakran; Melanie L Hutton; Dena Lyras; Carl D Kirkwood; Jim P Buttery Journal: Hum Vaccin Immunother Date: 2016-11-11 Impact factor: 3.452
Authors: Miguel O'Ryan; Roberto Vidal; Felipe del Canto; Juan Carlos Salazar; David Montero Journal: Hum Vaccin Immunother Date: 2015 Impact factor: 3.452
Authors: Nita Bhandari; Temsunaro Rongsen-Chandola; Ashish Bavdekar; Jacob John; Kalpana Antony; Sunita Taneja; Nidhi Goyal; Anand Kawade; Gagandeep Kang; Sudeep Singh Rathore; Sanjay Juvekar; Jayaprakash Muliyil; Alok Arya; Hanif Shaikh; Vinod Abraham; Sudhanshu Vrati; Michael Proschan; Robert Kohberger; Georges Thiry; Roger Glass; Harry B Greenberg; George Curlin; Krishna Mohan; G V J A Harshavardhan; Sai Prasad; T S Rao; John Boslego; Maharaj Kishan Bhan Journal: Lancet Date: 2014-03-12 Impact factor: 79.321